Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- UBS -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2)	12/6/2002 4:50:27 PM
From: scaram(o)uche	Respond to of 19

One clinical oncologist familiar with the Affinitac test results told TheStreet.com that the lung cancer study has likely failed, based on unaudited test results that have been completed and available to Isis officials since early last month. This oncologist requested anonymity because the final results from the study have not been reported, but he has no investment position in Isis stock. Chuckle. Yeah, and neither did the fund manager who put Feuerstein in contact with the oncologist. :-)

To: Icebrg who wrote (2)	12/6/2002 5:04:28 PM
From: Icebrg	Respond to of 19

Isis Pharmaceuticals Statement Regarding UBS Warburg Report Friday December 6, 4:44 pm ET Isis and Lilly Remain Blinded to Affinitak(TM) Phase III Clinical Trial CARLSBAD, Calif., Dec. 6 /PRNewswire-FirstCall/ -- In response to a research note published today by a UBS Warburg analyst, which downgraded the company's stock based on anecdotal information obtained from clinical investigators, Isis Pharmaceuticals, Inc., (Nasdaq: ISIS - News) issues the following statement regarding the status of the 600-patient Phase III clinical trial of Affinitak in combination with chemotherapy in patients with non-small cell lung cancer:The Phase III clinical trial remains blinded to both companies. No clinical investigator nor company representative has access to all the data. Further, no analysis of any kind has been initiated. -- The Phase III study design prevents insights. The study and data management systems have been designed to make it impossible for any clinical investigator to have sufficient information to draw any inference about the trial. In fact, the trial design prevents any single site from enrolling more than 5% of the total number of patients. Therefore, no clinical investigator could have sufficient experience to draw any conclusions about the performance of Affinitak. -- The trial database is secure. The database is maintained at Isis only. All Isis employees are blinded. No one at the company has sufficient access to unblind the data. We have confirmed that there has been no breach of security. We further confirm that no one at Isis or Lilly has unblinded information about this trial. -- The analysis and new drug application (NDA) plans have been finalized. Isis and Lilly have just completed important meetings that finalized the analysis plan for this trial, and the strategy for compiling a NDA should the results be sufficiently positive to support a single study filing. The companies plan to conduct the analysis of the Phase III data in March 2003. Based on detailed planning, the March timeframe has been adopted to support the maturation of the study and to coincide with the preparation of the CMC, or manufacturing section, of the NDA. -- Isis and Lilly remain enthusiastic about the potential for Affinitak in cancer. The Lilly Phase III trial of Affinitak in combination with Gemzar/cisplatin in patients with non-small cell lung cancer continues to enroll well. Additional Phase II trials of Affinitak are in progress and the work necessary to support a single study NDA is well underway.